Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Relapsed/Refractory Multiple Myeloma (Rollover Study)
NCT00063726Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2002
- Primary completion
- May 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Millennium Pharmaceuticals. Primary endpoints: Overall Survival and 1-Year Survival Rate. Started Apr 2002; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00063726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063726.